Pms7 - Loss of Qalys Associated With Biosimilar Discontinuation Due to Nocebo Effect

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1721
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Php184 - Patient Influence on Biosimilar Uptake: The Nocebo Effect

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Alendronate Prevents Loss of Bone Density Associated With Discontinuation of Hormone Replacement Therapy

Archives of Internal Medicine
2003English

Erratum To: Medication Use Following Bariatric Surgery: Factors Associated With Early Discontinuation

Obesity Surgery
NutritionEndocrinologyDieteticsSurgeryMetabolismDiabetes
2014English

Infusion Reactions Related to Infliximab Therapy Are Not Usually Associated With Drug Discontinuation

Journal of Rheumatology
RheumatologyAllergyImmunology
2012English

Estimate of Maximum Insurance Loss Due to Bushfires

2011English

Discontinuation of a Randomised Controlled Trial in General Practice Due to Unsuccessful Patient Recruitment

BJGP Open
2017English

The PROMIS of QALYs

Health and Quality of Life Outcomes
MedicineEnvironmentalPublic HealthOccupational Health
2015English

Quantifying Interpretability Loss Due to Image Compression

2012English

Letter: Is There a Role for Infliximab Biosimilar in Patients With Inflammatory Bowel Disease With Secondary Loss of Response to Infliximab Innovator?

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy